Thanks to a landmark deal announced on July 9 by the Global Fund, Uganda is expected to be among the first countries in sub-Saharan Africa to get access to Lenacapavir, a revolutionary new drug that has proven to offer protection against HIV infection.
The long-acting injectable—developed by U.S. drugmaker Gilead Sciences—was recently approved by the U.S. Food and Drug Administration (FDA) and, for the first time in history, it is being rolled out simultaneously in both wealthy and low- and middle-income countries.
